CORONA Remedies commercialises India's Most Advanced EU-GMP Approved Women's Hormone Manufacturing Facility

Reinforcing its long-term commitment to advancing women's healthcare, CORONA Remedies Limited today announced the inauguration and commercialisation of its dedicated EU-GMP approved Hormone Manufacturing Facility at Bhayla, Ahmedabad. The facility marks a significant milestone in the Company's journey towards building globally benchmarked pharmaceutical manufacturing capabilities.

The state-of-the-art facility was inaugurated by Chairman, Dr. K. L. Mehta, alongside longserving women employees of the organisation-symbolising CORONA's enduring commitment to women's health and the invaluable contribution of women in shaping the Company's success.

Responding to the Growing Need for Women's Healthcare

As global attention towards women's healthcare continues to grow, driven by greater awareness and diagnosis of hormonal disorders, increasing demand for fertility care and expanding focus on menopause management and hormone replacement therapies, the need for specialised, high-quality pharmaceutical manufacturing has become more critical than ever (as per WHO factsheet on Infertility Nov. 2025). As therapies become increasingly specialised, manufacturing excellence has emerged as a critical pillar alongside clinical innovation.

Hormonal medicines are among the most complex pharmaceutical products to manufacture. Their high potency, sensitive formulations and stringent contamination control requirements demand dedicated facilities equipped with sophisticated technologies, specialised engineering systems and uncompromising regulatory standards.

Recognising this evolving need, CORONA Remedies has established one of India's most advanced dedicated hormone manufacturing facilities, strengthening its capabilities to serve both domestic and international markets.

A Purpose-Built Manufacturing Ecosystem

Unlike conventional pharmaceutical manufacturing plants, dedicated hormone manufacturing requires complete segregation of operations, precision environmental controls, specialised containment technologies and highly trained personnel to ensure safe handling of potent hormone active pharmaceutical ingredients (APIs).

CORONA's integrated manufacturing platform supports multiple dosage forms-including tablets, soft gel capsules, ointments and gels-within a single specialised manufacturing ecosystem, enabling the Company to cater to a broad spectrum of women's healthcare therapies.

Spread across 1.0 lakh sq. ft; the facility has an annual manufacturing capacity of 194 million tablets/capsules and 1.5 million ointments/gels. With the commissioning of this facility, CORONA's in-house hormone manufacturing capacity is expected to increase by nearly 20%.

Advanced Manufacturing Technologies

The facility incorporates next-generation manufacturing technologies and digital process controls to ensure product consistency, precision and operational excellence.

Key capabilities include:

- Fully integrated closed-loop manufacturing systems supported by 21 CFR-compliant equipment and Quality by Design (QbD) principles.

- Advanced gelatin processing systems with precision-controlled agitation and jacketed vessels for accurate temperature management, superior uniformity and formulation consistency.

- Real-time online process monitoring for enhanced batch-to-batch reproducibility and product quality.

Speaking on the occasion, Mr. Nirav K. Mehta, Founder, Managing Director & CEO, CORONA Remedies Limited said: "Women's healthcare continues to be one of the fastest evolving areas of modern medicine. At CORONA, we believe scientific innovation must be complemented by world-class manufacturing capabilities. This dedicated hormone facility represents our commitment to delivering globally benchmarked quality, strengthening India's pharmaceutical manufacturing ecosystem and ensuring women have access to safe, reliable and high-quality hormone therapies."

Shares of CORONA Remedies Limited was last trading in BSE at Rs. 1963.55 as compared to the previous close of Rs. 1969.75. The total number of shares traded during the day was 1619 in over 336 trades.

The stock hit an intraday high of Rs. 1999.15 and intraday low of 1953.60. The net turnover during the day was Rs. 3190789.00.

Source : Equity Bulls

Keywords

CORONARemedies INE02ZQ01018 Pharmaceuticals Commercialization EUGMP